Angiogenesis and invasion in cancer

Handbook of Clinical Neurology

Volumn 104, Issue , 2012, Pages 35-43

  Bikfalvi, Andreas ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84855525590     PISSN: 00729752     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-52138-5.00003-7     Document Type: Chapter

References (67)

1. Adams R.H., Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 2007, 8:464-478.
2. Auguste P., Lemiere S., Larrieu-Lahargue F., et al. Molecular mechanisms of tumor vascularization. Crit Rev Oncol Hematol 2005, 54:53-61.
3. Autiero M., Luttun A., Tjwa M., et al. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: Novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost 2003, 1:1356-1370.
4. Autiero M., De Smet F., Claes F., et al. Role of neural guidance signals in blood vessel navigation. Cardiovasc Res 2005, 65:629-638.
5. Bello L., Carrabba G., Giussani C., et al. Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res 2001, 61:7501-7506.
6. Bergers G., Song S., Meyer-Morse N., et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003, 11:1287-1295.
7. Berra E., Ginouves A., Pouyssegur J. The hypoxia-inducible-factor hydroxylases bring fresh air into hypoxia signalling. EMBO Rep 2006, 7:41-45.
8. Bikfalvi A. Angiogenese tumorale. Bull Cancer 2003, 90:449-458.
9. Bikfalvi A., Bicknell R. Recent advances in angiogenesis, anti-angiogenesis and vascular targeting. Trends Pharmacol Sci 2002, 23:576-582.
10. Bjorndahl M., Cao R., Nissen L.J., et al. Insulin-like growth factors 1 and 2 induce lymphangiogenesis in vivo. Proc Natl Acad Sci U S A 2005, 102:15593-15598.
11. Blagosklonny M.V. Antiangiogenic therapy and tumor progression. Cancer Cell 2004, 5:13-17.
12. Burgess T., Coxon A., Meyer S., et al. Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors. Cancer Res 2006, 66:1721-1729.
13. Bussolati B., Deambrosis I., Russo S., et al. Altered angiogenesis and survival in human tumor-derived endothelial cells. FASEB J 2003, 17:1159-1161.
14. Cao L., Jiao X., Zuzga D.S., et al. VEGF links hippocampal activity with neurogenesis, learning and memory. Nat Genet 2004, 36:827-835.
15. Cao R., Björndahl M.A., Gallego M.I., et al. Hepatocyte growth factor is a novel lymphangiogenic factor with an indirect mechanism of action. Blood 2006, 107:3531-3536.
16. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005, 69:4-10.
17. Casanovas O., Hicklin D.J., Bergers G., et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8:299-309.
18. Corsten M.F., Miranda R., Kasmieh R., et al. MicroRNA-21 knockdown disrupts glioma growth in vivo and displays synergistic cytotoxicity with neural precursor cell delivered S-TRAIL in human gliomas. Cancer Res 2007, 67:8994-9000.
19. Dadras S.S., Paul T., Bertoncini J., et al. Tumor lymphangiogenesis: A novel prognostic indicator for cutaneous melanoma metastasis and survival. Am J Pathol 2003, 162:1951-1960.
20. Drogat B., Auguste P., Nguyen D.T., et al. IRE1 signaling is essential for ischemia-induced vascular endothelial growth factor-A expression and contributes to angiogenesis and tumor growth in vivo. Cancer Res 2007, 67:6700-6707.
21. Erber R., Thurnher A., Katsen A.D., et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004, 18:338-340.
22. Ferrara N. Vascular endothelial growth factor: Basic science and clinical progress. Endocr Rev 2004, 25:581-611.
23. Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS 2005, 94:209-231.
24. Folkman J. Tumor angiogenesis: Therapeutic implications. N Engl J Med 1971, 285:1182-1186.
25. Folkman J., Merler E., Abernathy C., et al. Isolation of a tumor factor responsible for angiogenesis. J Exp Med 1971, 133:275-288.
26. Folkman J., Watson K., Ingber D., et al. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989, 339:58-61.
27. Gondi C.S., Kandhukuri N., Dinh D.H., et al. Down-regulation of uPAR and uPA activates caspase-mediated apoptosis and inhibits the PI3K/AKT pathway. Int J Oncol 2007, 31:19-27.
28. Handsley M.M., Edwards D.R. Metalloproteinases and their inhibitors in tumor angiogenesis. Int J Cancer 2003, 115:849-860.
29. Hendrix M.J., Seftor E.A., Hess A.R., et al. Vasculogenic mimicry and tumour-cell plasticity: Lessons from melanoma. Nat Rev Cancer 2003, 3:411-421.
30. Hirakawa S., Hong Y.K., Harvey N., et al. Identification of vascular lineage-specific genes by transcriptional profiling of isolated blood vascular and lymphatic endothelial cells. Am J Pathol 2003, 162:575-586.
31. Hirakawa S., Kodama S., Kunstfeld R., et al. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J Exp Med 2005, 201:1089-1099.
32. Hoffmann J., Feng Y., vom Hagen F., et al. Endothelial/pericyte interactions. Circ Res 2005, 97:512-523.
33. Holash J., Maisonpierre P.C., Compton D., et al. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. Science 1999, 284:1994-1998.
34. Hong Y.K., Shin J.W., Detmar M. Development of the lymphatic vascular system: A mystery unravels. Dev Dyn 2004, 231:462-473.
35. Hynes R.O. Cell-matrix adhesion in vascular development. J Thromb Haemost 2007, 5:32-40.
36. Kalas W., Yu J.L., Milsom C., et al. Oncogenes and angiogenesis: Down-regulation of thrombospondin-1 in normal fibroblasts exposed to factors from cancer cells harboring mutant ras. Cancer Res 2005, 65:8878-8886.
37. Kim L., Glantz M. Chemotherapeutic options for primary brain tumors. Curr Treat Options Oncol 2006, 7:467-478.
38. Kim E.S., Serur A., Huang J., et al. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci U S A 2002, 99:11399-11404.
39. Kubo H., Cao R., Brakenhielm E., et al. Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. Proc Natl Acad Sci U S A 2002, 99:8868-8873.
40. Kunkel P., Ulbricht U., Bohlen P., et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res 2001, 61:6624-6628.
41. Lamszus K., Kunkel P., Westphal M. Invasion as limitation to anti-angiogenic glioma therapy. Acta Neurochir Suppl 2003, 88:169-177.
42. Leenders W.P., Kusters B., de Waal R.M. Vessel co-option: How tumors obtain blood supply in the absence of sprouting angiogenesis. Endothelium 2002, 9:83-87.
43. Lin J., Lalani A.S., Harding T.C., et al. Inhibition of lymphogenous metastasis using adeno-associated virus-mediated gene transfer of a soluble VEGFR-3 decoy receptor. Cancer Res 2005, 65:6901-6909.
44. Lu X., Le Noble F., Yuan L., et al. The netrin receptor UNC5B mediates guidance events controlling morphogenesis of the vascular system. Nature 2004, 432:179-186.
45. Mandriota S.J., Jussila L., Jeltsch M., et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J 2001, 20:672-682.
46. Martens T., Schmidt N.O., Eckerich C., et al. Novel one-armed anti-c-Met antibody inhibits glioblastoma growth in vivo. Clin Cancer Res 2006, 12:6144-6152.
47. Miraux S., Lemière S., Pineau R., et al. Inhibition of FGF receptor activity in glioma implanted into the mouse brain using the tetracyclin-regulated expression system. Angiogenesis 2004, 7:105-113.
48. Nabors L.B., Mikkelsen T., Rosenfeld S.S., et al. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol 2007, 25:1651-1657.
49. Neri D., Bicknell R. Tumour vascular targeting. Nat Rev Cancer 2005, 5:436-446.
50. Nisato R.E., Hosseini G., Sirrenberg C., et al. Dissecting the role of matrix metalloproteinases (MMP) and integrin α(v)β3 in angiogenesis in vitro: Absence of hemopexin C domain bioactivity, but membrane-Type 1-MMP and α(v)β3 are critical. Cancer Res 2005, 65:9377-9387.
51. North S., Moenner M., Bikfalvi A. Recent developments in the regulation of the angiogenic switch by cellular stress factors in tumors. Cancer Lett 2005, 218:1-14.
52. Oliver G., Alitalo K. The lymphatic vasculature: Recent progress and paradigms. Annu Rev Cell Dev Biol 2005, 21:457-483.
53. Petrova T.V., Mäkinen T., Mäkelä T.P., et al. Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. EMBO J 2002, 21:4593-4599.
54. Rafii S., Lyden D., Benezra R., et al. Vascular and haematopoietic stem cells: Novel targets for anti-angiogenesis therapy?. Nat Rev Cancer 2002, 2:826-835.
55. Rao J.S. Molecular mechanisms of glioma invasiveness: The role of proteases. Nat Rev Cancer 2003, 3:489-501.
56. Rubenstein J.L., Kim J., Ozawa T., et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000, 2:306-314.
57. Shin J.W., Min M., Larrieu-Lahargue F., et al. Prox1 promotes lineage-specific expression of fibroblast growth factor (FGF) receptor-3 in lymphatic endothelium: A role for FGF signaling in lymphangiogenesis. Mol Biol Cell 2006, 17:576-584.
58. Stupack D.G., Cheresh D.A. Integrins and angiogenesis. Curr Top Dev Biol 2004, 64:207-238.
59. Stupack D.G., Cheresh D.A. A bit-role for integrins in apoptosis. Nat Cell Biol 2004, 6:388-389.
60. Suchting S., Bicknell R., Eichmann A. Neuronal clues to vascular guidance. Exp Cell Res 2005, 312:668-675.
61. Tammela T., Saaristo A., Lohela M., et al. Angiopoietin-1 promotes lymphatic sprouting and hyperplasia. Blood 2005, 105:4642-4648.
62. Taverna D., Crowley D., Connolly M., et al. A direct test of potential roles for beta3 and beta5 integrins in growth and metastasis of murine mammary carcinomas. Cancer Res 2005, 65:10324-10329.
63. Thurston G. Role of angiopoietins and tie receptor tyrosine kinases in angiogenesis and lymphangiogenesis. Cell Tissue Res 2003, 4:61-68.
64. Vajkoczy P., Farhadi M., Gaumann A., et al. Microtumor growth initiates angiogenic sprouting with simultaneous expression of VEGF, VEGF receptor-2, and angiopoietin-2. J Clin Invest 2002, 109:777-785.
65. Vajkoczy P., Knyazev P., Kunkel A., et al. Dominant-negative inhibition of the axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival. Proc Natl Acad Sci U S A 2006, 103:5799-5804.
66. Yuan L., Siegel M., Choi K., et al. Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy. Oncogene 2007, 26:2563-2573.
67. Zagzag D., Amirnovin S.R., Greco M.A., et al. Vascular apoptosis and involution in gliomas precede neovascularization: A novel concept for glioma growth and angiogenesis. Lab Invest 2000, 80:837-849.